In addition, cytoreductive therapy was recommended in patients aged 60 years and above [94] although not judged mandatory by Barbui et Tefferi in the absence of cardiovascular risk factors, a history of thrombosis, and JAK2 mutations [11]. The gene discussed is JAK2; the disease is Venous thrombosis.